CDK7 is the catalytic subunit of the cyclin-H/MAT1 CDK-activating kinase complex. It phosphorylates cell-cycle CDKs and, in association with TFIIH, the C-terminal domain of RNA polymerase II. The selected horse protein conserves the human catalytic domain and has an additional C-terminal segment.
Summary: Nucleotide binding is explained by the conserved ATP-binding site of the kinase.
Reason: Nucleotide binding is explained by the conserved ATP-binding site of the kinase. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
GO:0000307 cyclin-dependent protein kinase holoenzyme complex
IEA GO_REF:0000107
ACCEPT
Summary: CDK7 forms the cyclin-H/MAT1 CDK-activating kinase assembly.
Reason: CDK7 forms the cyclin-H/MAT1 CDK-activating kinase assembly. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: QuickGO defines the seven-subunit TFIIH core without CDK7. CDK7 belongs to the CAK module of holo-TFIIH, not the seven-subunit core.
Reason: QuickGO defines the seven-subunit TFIIH core without CDK7. CDK7 belongs to the CAK module of holo-TFIIH, not the seven-subunit core. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: The specific fibrillar-center localization is not established by the catalytic-domain comparison or the accessible CDK7 structural study.
Reason: The specific fibrillar-center localization is not established by the catalytic-domain comparison or the accessible CDK7 structural study. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10958787, CC ECO:0000269|PubMed:15695176, ECO:0000269|PubMed:19071173}. Cytoplasm CC {ECO:0000269|PubMed:15695176}. Cytoplasm, perinuclear region CC {ECO:0000269|PubMed:19071173}. Note=Colocalizes with PRKCI in the CC cytoplasm and nucleus (PubMed:15695176). Translocates from the nucleus CC to cytoplasm and perinuclear region in response to DNA-bound peptides CC (PubMed:19071173). {ECO:0000269|PubMed:15695176, CC ECO:0000269|PubMed:19071173}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
Summary: The conserved kinase is a cyclin-dependent serine/threonine kinase; the broad protein kinase term can be made specific.
Reason: The conserved kinase is a cyclin-dependent serine/threonine kinase; the broad protein kinase term can be made specific. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
GO:0004674 protein serine/threonine kinase activity
IEA GO_REF:0000120
MODIFY
Summary: Cyclin dependence is a conserved characteristic of CDK7.
Reason: Cyclin dependence is a conserved characteristic of CDK7. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
GO:0004693 cyclin-dependent protein serine/threonine kinase activity
IEA GO_REF:0000003
ACCEPT
Summary: Human CDK7 structure and enzymology establish cyclin-dependent phosphorylation; the horse catalytic Asp137 and ATP-binding site are conserved.
Reason: Human CDK7 structure and enzymology establish cyclin-dependent phosphorylation; the horse catalytic Asp137 and ATP-binding site are conserved. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: The human ATP-bound structure identifies binding residues that are retained in the horse sequence.
Reason: The human ATP-bound structure identifies binding residues that are retained in the horse sequence. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: Nuclear transcriptional and cell-cycle functions are characteristic of CDK7 and its conserved CAK/TFIIH associations.
Reason: Nuclear transcriptional and cell-cycle functions are characteristic of CDK7 and its conserved CAK/TFIIH associations. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10958787, CC ECO:0000269|PubMed:15695176, ECO:0000269|PubMed:19071173}. Cytoplasm CC {ECO:0000269|PubMed:15695176}. Cytoplasm, perinuclear region CC {ECO:0000269|PubMed:19071173}. Note=Colocalizes with PRKCI in the CC cytoplasm and nucleus (PubMed:15695176). Translocates from the nucleus CC to cytoplasm and perinuclear region in response to DNA-bound peptides CC (PubMed:19071173). {ECO:0000269|PubMed:15695176, CC ECO:0000269|PubMed:19071173}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: Nucleoplasmic activity is consistent with the conserved transcription-associated CDK7 complex.
Reason: Nucleoplasmic activity is consistent with the conserved transcription-associated CDK7 complex. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10958787, CC ECO:0000269|PubMed:15695176, ECO:0000269|PubMed:19071173}. Cytoplasm CC {ECO:0000269|PubMed:15695176}. Cytoplasm, perinuclear region CC {ECO:0000269|PubMed:19071173}. Note=Colocalizes with PRKCI in the CC cytoplasm and nucleus (PubMed:15695176). Translocates from the nucleus CC to cytoplasm and perinuclear region in response to DNA-bound peptides CC (PubMed:19071173). {ECO:0000269|PubMed:15695176, CC ECO:0000269|PubMed:19071173}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: CDK7 is the kinase subunit of the CAK module associated with TFIIH holo complex.
Reason: CDK7 is the kinase subunit of the CAK module associated with TFIIH holo complex. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: A cytosolic CDK7 pool is compatible with the cellular distribution reported for human CDK7, but does not define its primary transcriptional role.
Reason: A cytosolic CDK7 pool is compatible with the cellular distribution reported for human CDK7, but does not define its primary transcriptional role. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10958787, CC ECO:0000269|PubMed:15695176, ECO:0000269|PubMed:19071173}. Cytoplasm CC {ECO:0000269|PubMed:15695176}. Cytoplasm, perinuclear region CC {ECO:0000269|PubMed:19071173}. Note=Colocalizes with PRKCI in the CC cytoplasm and nucleus (PubMed:15695176). Translocates from the nucleus CC to cytoplasm and perinuclear region in response to DNA-bound peptides CC (PubMed:19071173). {ECO:0000269|PubMed:15695176, CC ECO:0000269|PubMed:19071173}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
GO:0006367 transcription initiation at RNA polymerase II promoter
IEA GO_REF:0000107
ACCEPT
Summary: CDK7 phosphorylation of RNA polymerase II CTD promotes transcription initiation.
Reason: CDK7 phosphorylation of RNA polymerase II CTD promotes transcription initiation. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: QuickGO defines this as ATP-driven catalytic modification of DNA. CDK7 phosphorylates protein substrates; the ATP-dependent DNA activities of TFIIH reside in other subunits.
Reason: QuickGO defines this as ATP-driven catalytic modification of DNA. CDK7 phosphorylates protein substrates; the ATP-dependent DNA activities of TFIIH reside in other subunits. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
GO:0008353 RNA polymerase II CTD heptapeptide repeat kinase activity
IEA GO_REF:0000120
ACCEPT
Summary: CDK7 phosphorylates the RNA polymerase II CTD in its conserved transcriptional role.
Reason: CDK7 phosphorylates the RNA polymerase II CTD in its conserved transcriptional role. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: The retained CDK7 catalytic domain supports the more informative cyclin-dependent protein kinase term.
Reason: The retained CDK7 catalytic domain supports the more informative cyclin-dependent protein kinase term. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: The transferred group is phosphate and the kinase class is known.
Reason: The transferred group is phosphate and the kinase class is known. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
GO:0045944 positive regulation of transcription by RNA polymerase II
IEA GO_REF:0000107
ACCEPT
Summary: CTD phosphorylation promotes RNA polymerase II transcription; this is central to the CDK7 mechanism.
Reason: CTD phosphorylation promotes RNA polymerase II transcription; this is central to the CDK7 mechanism. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: Protein stabilization is substrate- and context-dependent; conserved kinase activity alone does not identify the relevant stabilization mechanism.
Reason: Protein stabilization is substrate- and context-dependent; conserved kinase activity alone does not identify the relevant stabilization mechanism. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
Summary: CDK7 is part of the conserved CAK module that associates with ERCC2/XPD.
Reason: CDK7 is part of the conserved CAK module that associates with ERCC2/XPD. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Summary: The TFIIK/CAK kinase module contains CDK7, cyclin H and MAT1.
Reason: The TFIIK/CAK kinase module contains CDK7, cyclin H and MAT1. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
GO:0140836 RNA polymerase II CTD heptapeptide repeat S5 kinase activity
IEA GO_REF:0000107
ACCEPT
Summary: The human enzyme phosphorylates CTD Ser5; the horse CDK7 catalytic architecture supports this conserved substrate role.
Reason: The human enzyme phosphorylates CTD Ser5; the horse CDK7 catalytic architecture supports this conserved substrate role. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
GO:2000045 regulation of G1/S transition of mitotic cell cycle
IEA GO_REF:0000107
ACCEPT
Summary: CDK activation by CDK7 links its kinase activity to G1/S cell-cycle control.
Reason: CDK activation by CDK7 links its kinase activity to G1/S cell-cycle control. This assessment transfers characterized mammalian biology to the selected horse sequence with the sequence limitations stated in the comparison.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
Core Functions
CDK7 is the catalytic subunit of the cyclin-H/MAT1 CDK-activating kinase complex. It phosphorylates cell-cycle CDKs and, in association with TFIIH, the C-terminal domain of RNA polymerase II. The selected horse protein conserves the human catalytic domain and has an additional C-terminal segment.
CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}.
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md
The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence.
CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1.
These computational predictions are reviewed separately from the GOA annotation set used for this review. The assessments below are from this project and do not constitute official GO annotations or endorsement by GO/UniProt. They are not included in the existing annotation review above.
Assessment of 2 ProtNLM GO predictions for the selected horse CDK7 protein, using mammalian experimental findings and an explicit comparison of the horse sequence.
Review score: 2 = concordant with evidence; 1 = uncertain; 0 = discordant with evidence. This is an assessment score, not a model probability.
GO:0004693 cyclin-dependent protein serine/threonine kinase activityGO_MF
CNN — Correct but not novel Review score: 2/2
Prediction method: ProtNLM2 · Version: UniProt API snapshot 2026-09-08
Review rationale: The cyclin-dependent kinase activity is supported by human CDK7 structural and biochemical work (PMID:15530371), the conserved horse catalytic Asp137 and ATP-binding residues, and 95.38% identity over the complete human reference. The horse protein has an additional segment, but the catalytic domain is retained. The exact term is already in horse GOA. Training-set membership is unknown.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt: "CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}."
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md: "The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence."
PMID:15530371: "CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1."
Prediction method: ProtNLM2 · Version: UniProt API snapshot 2026-09-08
Review rationale: Human CDK7 phosphorylates CDKs and the RNA polymerase II CTD; the horse catalytic domain and ATP-binding features are conserved. Protein phosphorylation is therefore a justified mammalian functional transfer. This BP term is absent from the frozen horse GOA, although kinase MF annotations are present; novelty here means target annotation coverage, not a new biochemical discovery or known absence from training. Training-set membership is unknown.
Supporting Evidence:
file:human/CDK7/CDK7-uniprot.txt: "CC -!- FUNCTION: Serine/threonine kinase involved in cell cycle control and in CC RNA polymerase II-mediated RNA transcription (PubMed:9852112, CC PubMed:19136461, PubMed:26257281, PubMed:28768201). As a cyclin- CC dependent kinase, CDK7 is activated by the binding to cyclin-H/CCNH and CC the CDK-activating kinase assembly factor MAT1 (PubMed:41100585). CC Catalytic subunit of the CDK-activating kinase (CAK) complex, a master CC regulator of CDK activity by catalyzing the activating threonine CC phosphorylation of CDKs (PubMed:41100585). CAK activates major CC mediators of cell cycle control, including CDK1, CDK2, CDK4 and CDK6, CC and plays a key role in regulating cell cycle progression CC (PubMed:41100585). CAK complexed to the core-TFIIH basal transcription CC factor activates RNA polymerase II by serine phosphorylation of the CTD CC of POLR2A, allowing its escape from the promoter and elongation of the CC transcripts (PubMed:9852112). Initiates transcription by RNA polymerase CC II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive CC C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting CC dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, CC PubMed:28768201). Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, CC p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, CC PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201, CC PubMed:41100585, PubMed:41100585). Its expression and activity are CC constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 CC activation by phosphorylation, but is inactivated in turn by p53/TP53; CC this feedback loop may lead to an arrest of the cell cycle and of the CC transcription, helping in cell recovery, or to apoptosis. Required for CC DNA-bound peptides-mediated transcription and cellular growth CC inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, CC ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, CC ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, CC ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, CC ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, CC ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, CC ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, CC ECO:0000269|PubMed:41100585, ECO:0000269|PubMed:9372954, CC ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}."
file:HORSE/CDK7/CDK7-bioinformatics/RESULTS.md: "The horse sequence A0A9L0R074 (415 residues) aligns to human P50613 (346 residues) with 95.38% identity across 346 paired residues. Paired coverage is 100.0% of the human sequence and 83.37% of the horse sequence."
PMID:15530371: "CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle. CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex. For maximum activity and stability, CDK7 requires phosphorylation, association with cyclin H, and association with a third protein, MAT1."